Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$30.15
+0.05 (+0.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $242.2M · quality 67.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$15.2B
P/E
18.2x
↓EV/EBITDA
13.2x
↑ROE
9.4%
↑Gross Margin
43.3%
↓Debt/Equity
0.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.2%
FCF CAGR
-33.6%
FCF margin
2.1%
FCF / Net income
0.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.19B · net income $821.8M · FCF $130.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.19B | $6.19B | $5.55B | $5.14B | $4.39B |
| Net Income | $821.8M | $821.8M | $684.7M | $594.8M | $799.1M |
| EBITDA | $1.20B | $1.20B | $1.06B | $1.01B | $1.10B |
| EPS | — | — | 1.48 | 1.32 | 1.84 |
| Gross Margin | 43.3% | 43.3% | 43.3% | 41.2% | 41.6% |
| Operating Margin | 12.6% | 12.6% | 13.3% | 12.1% | 10.4% |
| Net Margin | 13.3% | 13.3% | 12.3% | 11.6% | 18.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.29 | 0.29 | 0.35 | 0.36 | 0.63 |
| Current Ratio | 2.60 | 2.60 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $130.4M | $130.4M | $511.0M | $242.2M | $445.9M |
| Returns | |||||
| ROE | 9.4% | 9.4% | 9.5% | 8.9% | 15.0% |
| Valuation | |||||
| P/E | 18.16 | 18.16 | 20.83 | 24.60 | 18.14 |
| EV/EBITDA | 13.18 | 13.18 | 14.79 | 16.01 | 15.18 |
| P/B | 1.74 | 1.74 | 1.98 | 2.18 | 2.73 |
| Growth & Yield | |||||
| Revenue Growth | 11.5% | 11.5% | 8.0% | 17.2% | — |
| EPS Growth | — | — | 12.1% | -28.3% | — |
| Dividend Yield | 2.0% | 2.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-1.0%
Start / end P/E
n/dx → n/dx
EPS bridge
1.48 → n/d
Residual
-3.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.